Ellen de Brabander - 01 Mar 2026 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Role: Executive Vice President, Research, Development and Regulatory Affairs
Signature: /s/ Amy C. Seidel, as Attorney-in-Fact for Ellen de Brabander
Issuer symbol: ELAN
Transactions as of: 01 Mar 2026
Net transactions value: -$1,221,739
Form type: 4
Filing time: 03 Mar 2026, 19:14:47 UTC
Previous filing: 06 Jan 2026
Next filing: 05 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
de Brabander Ellen	Executive Vice President, Research, Development and Regulatory Affairs	C/O ELANCO ANIMAL HEALTH INCORPORATED, 450 ELANCO CIRCLE, INDIANAPOLIS	/s/ Amy C. Seidel, as Attorney-in-Fact for Ellen de Brabander	03 Mar 2026	0001892179

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELAN	Common Stock	Award	$0	+67,564	+30%	$0.000000	289,304	01 Mar 2026	Direct
transaction	ELAN	Common Stock	Tax liability	$1,221,739	-46,278	-16%	$26.40	243,026	01 Mar 2026	Direct
transaction	ELAN	Common Stock	Award	$0	+25,360	+10%	$0.000000	268,386	01 Mar 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELAN	Employee Stock Option (right to buy)	Award	$0	+51,819		$0.000000	51,819	01 Mar 2026	Common Stock	51,819	$26.40	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.
F2	Grant of stock options vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

Remarks:

Executive Vice President, Research, Development and Regulatory Affairs